Eleonora Leucci<p>Excited to share our work of the of the last 5 years. <a href="https://www.biorxiv.org/content/10.1101/2023.01.06.523012v1" target="_blank" rel="nofollow noopener noreferrer" translate="no"><span class="invisible">https://www.</span><span class="ellipsis">biorxiv.org/content/10.1101/20</span><span class="invisible">23.01.06.523012v1</span></a>. We found that in response to the ISR, the primate-specific <a href="https://mastodon.uno/tags/lncRNA" class="mention hashtag" rel="tag">#<span>lncRNA</span></a> LISR customises the <a href="https://mastodon.uno/tags/ribosomes" class="mention hashtag" rel="tag">#<span>ribosomes</span></a> to drive translation of an immune suppressive signature. The signature includes <a href="https://mastodon.uno/tags/neoantigens" class="mention hashtag" rel="tag">#<span>neoantigens</span></a> translated from lncRNAs, the <a href="https://mastodon.uno/tags/immunecheckpoint" class="mention hashtag" rel="tag">#<span>immunecheckpoint</span></a> receptor PDL1 and the <a href="https://mastodon.uno/tags/glycocalyx" class="mention hashtag" rel="tag">#<span>glycocalyx</span></a>. LISR KD restores sensitivity to <a href="https://mastodon.uno/tags/immunecheckpointblockade" class="mention hashtag" rel="tag">#<span>immunecheckpointblockade</span></a> in <a href="https://mastodon.uno/tags/melanoma" class="mention hashtag" rel="tag">#<span>melanoma</span></a> and possibly in other cancers.</p>